SCHEMBL13638428

SCHEMBL13638428

C=C1CC(Nc2nccc(-c3ccc(-c4cccs4)s3)n2)CC(C)(C)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 6/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 4/20 0.37
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
GSK3B P49841 3/20 0.36
KDM4E B2RXH2 4/20 0.34
SYK P43405 1/20 0.34
CCNA2 P20248 5/20 0.34
CDK2 P24941 5/20 0.34
CCNA1 P78396 5/20 0.34
CDK1 P06493 4/20 0.34
CCNB1 P14635 4/20 0.34
CCND1 P24385 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638286 0.86 ROCK2 (0.35) CDK4CCNA2CDK2CCNA1CDK1
SCHEMBL13638420 0.86 KDM4E (0.38) CDK4GAANPC1RAB9AGSK3B
SCHEMBL3471600 0.86 CDK4 (0.43) CDK4MEN1KMT2AALDH1A1GAA
SCHEMBL13638501 0.85 HDAC8 (0.41) CYP3A4CYP2C19GSK3BCCNA2CDK2
SCHEMBL13638454 0.84 CDK4 (0.36) CDK4GSK3BCCNA2CDK2CCNA1
SCHEMBL14612785 0.84 IKBKB (0.37) CDK4MEN1KMT2AALDH1A1GSK3B
SCHEMBL13638673 0.84 CDK1 (0.33) CDK4CYP1A2CYP3A4CYP2C19CCNA2
SCHEMBL14612850 0.83 AKT3 (0.37) CDK4CYP3A4CYP2C19CCNA2CDK2
SCHEMBL13638302 0.83 IKBKB (0.46) CDK4CCNA2CDK2CCNA1CDK1
SCHEMBL14612849 0.83 IKBKB (0.35) CDK4CCNA2CDK2CCNA1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK CDK4 681/4885MEN1 4134/4885KMT2A 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.